Rebif

Thanks in advance, meadowstream posted: wed oct 27, 2004 4: post subject: i dont have a link but the study is called the evidence study and was required by the fda to show that rebif is more effective than avonex. `The role of botulinum toxin in the treatment of cerebral palsy. Frequently asked questions and answers for parents and children' is a new booklet available from Ipsen Limited. The booklet was developed together with Scope, the disability organisation in England and Wales. Cerebral palsy is caused by damage to the brain that takes place before, during or in the early days after birth. When the brain is damaged in this way, many children have `spasticity', where their arms and legs feel stiff and are difficult to move. Some movement may be possible, but tends to be quite limited and prevents them from independently joining many of the activities in which children participate. Botulinum toxin type A Dysport ; can be used to treat this spasticity in children of two years of age and older. The booklet will help parents and children understand why botulinum toxin injections have been recommended. It explains what botulinum toxin is, how it is used, how it works and what effects it has. At the end of the booklet there are some frequently asked questions. Copies of the leaflet can be obtained from Medical Information Department, Ipsen Ltd, 190 Bath Road, Slough, Berkshire, SL1 3XE. Tel: 01753 627777. Email: medical rmation ipsen and from Scope's website: scope. As presently pled, the complaint does not sufficiently establish that false claims were submitted for government payment in a way that satisfies the particularity requirement. Cf. id. at 233.

The coat protein from the filamentous phages fd, f 1, and Ml 3 is easily obtained and readily associates with lipids. These protein lipid complexes have been used frequently as model membranes for biophysical studies 1-8 ; . Here 13 we report that the fd coat protein undergoes an a conformational transition that depends on the lipid: protein ratio and on the nature of the lipid tail groups. "Amphomorphic" is proposed as a term for proteins that undergo environmentally mediated a f3 transitions. 20 dec 2007 merck serono has leading brands serving patients with cancer erbitux r , multiple sclerosis rebif r , infertility gonal-f r , metabolic and fox news early bird gets the ms worm - dec 5, 2007. By Jim Riddle Twenty four people attended the IOIA ICO Organic Farm Inspector Training in Indianapolis, IN December 4-7, 2006. Joyce Ford was the trainer, with able assistance from Margaret Scoles. Garry Lean, new IOIA trainer, gave a terrific presentation on Assessing Soil Fertility Management Programs including a handout on weeds as indicators of soil conditions. The course was held at the Adam's Mark Hotel in conjunction with the Acres USA Conference, which was held later in the week. A big thanks to Cissy Bowman and Aaron Zeis at ICO for their sponsorship and assistance for this training. Also many thanks to Val Carr and our chef who made organic meals in our hospitality suite. Two small groups went to One Sky Farm, owned and operated by Jeff and Melissa Evard. Although it was hard to assess soil fertility at 10F and with a light snow covering the soil, we did a great job with a sample balance of red beets, verifying organic seeds and inspecting several on-farm greenhouses. A third group toured the Roger Sharrit farm. The area received 7 inches of snow later in the week and refresh.
Treatment due to injection site reactions. In all other patients the reactions resolved and the patients completed 2 years of therapy. Flu-like symptoms" This syndrome is most commonly encountered early in therapy. However, in the study report, no analysis taking time into account is presented and it is therefore, due to the non-specific nature of the symptoms, hard to present a reasonable overview of incidence, duration and severity. However, overall fever was more commonly reported in the IFN groups, 25 and 28 % vs. 16% in the placebo group. Laboratory abnormalities As expected, peripheral haematology was affected by IFN treatment. Overall, lymphopenia was seen in 11, 20 and 29% of the patients, placebo, 6 MIU and 12 MIU, respectively. Of these 30% were severe in the 12 MIU group. A dose-related reduction in granulocyte count was also observed and 2 patients in the 12 MIU group reported severe granulocytopenia. Overall the incidence of granulocytopenia was 4, 12 and 15%. No case of severe thrombocytopenia was reported, but the overall incidence was highest in the 12 MIU group, 8%. Anaemia was seen in similar incidence in the placebo and the 6 MIU groups 3% ; , but slightly more often in the 12 MIU group 5% ; . IFN increased the mean of ALAT, ASAT, and ALP, and elevation in ALAT ASAT was seen on at least one occasion in the 23% of the 22-mcg patients and 54% of the 44-mcg patients. These elevations were severe in 6 subjects in both IFN groups. Neutralising antibodies The liquid formulation of Rebif was used in this study and the immunogenicity was assessed at baseline and every 6 months. Samples, collected at least 24 hours after administration of study medication, were first tested at a central laboratory for binding antibodies ELISA ; and if positive were then tested for neutralising activity utilising a standard cytopathic protection assay. Results were, in the study report, not presented as titres of binding and neutralising antibodies, only as "positive patients" as regards neutralising antibodies. In the protocol, a positive patient was defined as one who maintained "positivity" for at least two consecutive visits. Given the protocol definition, 24 % of the patients in the 6 MIU group vs. 0 placebo ; and 15 % 12 MIU ; tested positive. If three or more positive results were required 14 and 11% tested positive, if four or more 9 and 4% observe that during the study period, testing were made at base line + every 6 months, i.e. altogether 5 times ; . At least one patient showed a positive test result for the first time at month 24 and a number of patients at month 18. On the data provided by the applicant and on the evaluation of the impact of binding and neutralising antibodies, the CPMP required the company to submit validations for the methods of analyses for binding and neutralising antibodies. Additional data on the incidence and titres of binding and neutralising antibodies over time were also requested. The Sponsor, in response, submitted validation reports for the assays and tables with individual patient data with titres for binding and neutralising antibodies NAb ; . The antibody assays were found to be reasonably documented and validated. The biological validity of the in vitro testing for NAb has also been corroborated in vivo by pharmacodynamic studies showing an attenuated dynamic response to IFN beta in NAb + patients. Overall, high levels of binding antibodies were found to be strongly associated with positivity for NAb. There also seem to be roughly two populations of NAb + patients, "low NAb titre responders" with a low highest titre below, e.g. 20 NU ml ; and in most cases transient NAb positivity and "high NAb titre responders" where the titre tends to increase with time on therapy. Thus, in patients with a highest titre below 20 NU ml, 13 in the 12 MIU group and 8 10 in the 6 MIU group lost antibody positivity while on therapy. Conversely, in patients with at least one titre equal to or above 20 NU ml, 4 49 in the 6 MIU group and 9 32 in the 12 MIU group lost antibody positivity. At 24 months, altogether 45 189 thereof two with a highest titre 20 ; were NAb + in the 6 MIU group and 23 184 in the 12 MIU group thereof none with a highest titre 20.
` 15 bis chemin des Mines, Case Postale 54, CH-1211 Geneve 20 Tel: 022 ; 739 30 00; 022 ; 739 36 01 Investor Relations ; International Tel: + 41 22 ; 739 30 00; + 41 22 ; 739 36 01 Investor Relations ; Telex: 412 141 asg ch Fax: 022 ; 739 21 79 739 30 22 Investor Relations ; International Fax: + 41 22 ; 739 21 79; + 41 22 ; 739 30 22 Investor Relations ; Company Email: media.relations serono ; investor.relations serono Web Site: serono Board of Directors: Georges Muller Chairman ; , Ernesto Bertarelli Vice Chairman of the Board and Chief Executive Officer ; , Pierre Douaze, Bernard Mach, Hans Thierstein, Sergio Marchionne, Jacques Theurillat Executive Committee: Ernesto Bertarelli Chief Executive Officer ; , Franck Latrille Senior Executive Vice President Global Product Development ; , Francois Naef Senior Executive Vice President Human Resources, Legal and Corporate Communication ; , Jacques Theurillat Deputy Chief Executive Officer, President European and International Sales and Marketing, Finance ; , Roland Baumann Senior Executive Vice President Compliance Officer and Head of Corporate Administration ; , Leon Bushara Senior Executive Vice President Business Development ; , Giampiero De Luca Chief Intellectual Property Counsel ; , Fereydoun Firouz President Serono Inc ; , Timothy Wells Senior Executive Vice President Research ; , Allan L Shaw Chief Financial Officer ; , Djan Yagtug Vice President Corporate Communications ; Key Personnel: Dr Andrew Galazka Senior Vice President of Investor Relations and Scientific Affairs ; , Fereydoun Firouz Vice President, Latin America ; , Warren Jenkins Vice President, Japan and Oceania ; , Aliza Eshkol Senior Scientific Advisor ; PRINCIPAL ACTIVITIES: Research, development, manufacture and sale of specialty pharmaceuticals to achieve innovative theraputic solutions for areas including infertility Joint Ventures: In August 2000 the company agreed to collaborate with Modex Therapeutics Ltd on the development of new technology in the area of protein expression. In October 2000 an agreement between British Biotech and Serono was announced to cooperate on the research, development and commercialisation of metalloenzyme inhibitors to be used in the treatment of inflammatory diseases. In September 2001 the company agreed with ZymoGenetics, USA, to co-develop products for treating auto-immune diseases. In October 2002 the company agreed a cooperation agreement with Cellular Genomics Inc to research four kinases. In March 2003 the company signed a marketing agreement with OSI Pharmaceuticals for Novantrone Trade Names: Gonal-F R ; , LHadi R ; , Ovidrel R ; , Serostim R ; , Rebif R ; , Saizen R ; , Pergonal R ; , Raptiva R ; , Serostim R ; , Metrodin R ; , Frone R ; , Profasi R ; , Stilamin R ; , Metrodin R ; HP, Geref R ; , Easyject R ; , Antide TM ; , TBP-1, Sigosix R ; , Component B, LAG-3, IFINAR2, HP Fertinex TM ; , Cetrotide R ; , Crinone R ; , ProLease R ; , Curosurf R ; , Stilamin R ; , Luveris R ; , cool.click R ; , Saizen R ; Parent Company: Bertarelli & Cie Principal Operating Companies: 100% owned unless stated ; : Genset SA France Serono GmbH Germany Serono Hellas AE Greece Serono Hong King Ltd Hong Kong SAR Serono Israel Ltd Israel Industria Farmaceutica Serono SpA 96.67% ; Italy Istituto di Ricerche Biomediche Antoine Marxer RBM SpA 96.82% ; Italy Serono Japan Co Ltd Japan Serono Korea Co Ltd Korea Serono de Mexico SA de CV Mexico Serono Produtos Farmaceuticos Ltda Portugal Serono Puerto Rico, a Branch of Ares Trading SA Puerto Rico Serono Singapore Pte Ltd Singapore Serono South Africa Pty ; Ltd South Africa Serono Espana SA Spain Serono Nordic AB Sweden Serono Singapore Pte Ltd Taiwan Serono Thailand ; Co Ltd; Serono Benelux BV Netherlands Serono Ilac Pazarlama ve Ticaret AS Turkey Serono Ltd UK Bourn Hall Clinic UK Serono Europe Ltd UK Ares Trading Uruguay SA Uruguay Serono Inc USA Serono Reproductive Biology Institute Inc USA Serono de Venezuela SA Venezuela ; Auditors: PricewaterhouseCoopers SA Financial Information: Consolidated figures in US Dollars except dividends per share in Swiss Francs 31.12.02 31.12.03 US$'000 US$'000 Total revenues 1, 537, 835 Profit before tax * 384, 441 459, Profit after tax 320, 778 389, Dividend per bearer share 7.00SF 8.00SF Earnings per share 20.07US$ 24.63US$ Share capital 253, 416 253, Shareholders funds 2, 461, 198 * and minority interests Status: Public company Ticker Symbol: SEO; NYSE: SRA; ISIN: ch0010751920 Principal Shareholders: Bertarelli & Cie 61.6% aggregate voting ; No of Employees: 4, 384 and relenza.
Posted: sun aug 07, 2005 1: post subject: combination of rebif and cellcept i on rebif since 199 i have had atack this june first time since i on rebif, because of that my neuro prescribed me cellcept 250mg x 2 times on day.

Range of proposals to encourage or create initiatives promoting health technology innovation for the poor. These include doublebottomline venture capital funds where both profits and social benefit are measured France's airline solidarity contribu tion [17]; humanitarian licensing practices at re search universities[18]; fasttrack regulatory ap proval vouchers[12]; global procurement funds such as GAVI and the Global Fund to Fight AIDS, TB, and Malaria; advance market commitments[19]; and oth ers. We do not know, however, which of these are most costeffective, which are synergistic, and which may crossreact to produce unwanted side effects[20]. The Era of Partnerships is structured by techno logical innovation, the legacy of the geopolitical struggle between capitalism and socialism, and glob alization. This last factor has affected many aspects of health worldwide. Jet travel can transmit diseases from one part of the world to another in a matter of hours. Pharmaceutical firms are now global compa nies, marketing their products to over 100 countries. Because of the very large profits they have made off of critically needed health products--especially by the poor--these companies have been admired and criticized. Globalization has led university investiga tors to collaborate through worldwide research sys tems, which has made science a global undertaking. All of these aspects of globalization are profoundly affecting how knowledge is produced and how health technology innovation occurs [21] [22]. We do not yet know how this new Era of Part nerships can operate most effectively in the field of health innovation. Insistent questions have arisen about how to best regulate new drugs and vaccines, how to manage patents and other forms of IP for new health applications, and how to fund research and remicade.

We began marketing rebif in the united states in march 200 at the end of 2002, over 13, 000 patients were being treated with rebif in the united states, and our estimated market share in terms of dollar-value of sales was about 5% for the whole year and renagel. HYPNOTICS Practice parameters for the treatment of sleep disorders are available at: : aasmnet Benzodiazepines temazepam generic of RESTORIL ; triazolam generic of HALCION ; Nonbenzodiazepines eszopiclone LUNESTA ; zolpidem generic of AMBIEN ; zolpidem ext-rel AMBIEN CR ; MIGRAINE Guidelines for prevention and management of migraine headaches are available at: : aan Ergotamine Derivatives dihydroergotamine inj generic of D.H.E. 45 ; dihydroergotamine spray MIGRANAL ; ergotamine caffeine generic of CAFERGOT ; Selective Serotonin Agonists eletriptan RELPAX ; frovatriptan FROVA ; rizatriptan MAXALT ; sumatriptan IMITREX ; zolmitriptan ZOMIG ; Miscellaneous OTC acetaminophen aspirin caffeine generic of EXCEDRIN MIGRAINE ; MOOD STABILIZERS lithium carbonate lithium carbonate ext-rel tabs 300 mg generic of LITHOBID ; lithium carbonate ext-rel tabs 450 mg MULTIPLE SCLEROSIS AGENTS Practice guidelines for multiple sclerosis are available at: : aan glatiramer COPAXONE ; interferon beta-1a REBIF ; interferon beta-1a AVONEX ; interferon beta-1b BETASERON ; MUSCULOSKELETAL THERAPY AGENTS baclofen carisoprodol generic of SOMA ; chlorzoxazone generic of PARAFON FORTE DSC ; cyclobenzaprine generic of FLEXERIL ; dantrolene generic of DANTRIUM ; metaxalone SKELAXIN ; methocarbamol generic of ROBAXIN ; orphenadrine aspirin caffeine tizanidine generic of ZANAFLEX ; MYASTHENIA GRAVIS pyridostigmine generic of MESTINON ; pyridostigmine ext-rel MESTINON TIMESPAN. Site 4 is located off Old Gurnet Road between the intersection of Orion Street and Sandy Road. Site 4 is a former disposal pit that was 4 ft. long, 4 ft. wide, and 3.5 ft. deep and was used from 1969 to 1974 for disposing of acids, solvents, and transformer oils Weston 1983 ; . The quantities of waste disposed of were not recorded. The former location of the excavated disposal pit is now covered by the eastern portion of the Building 584 Jordan 1990, Mosher 2006a ; . A remedial investigation feasibility study was completed in 1988 and 1989 which included a soil gas survey, soil boring and well installation, soil sampling, and groundwater sampling for organic and inorganic constituents Jordan 1990 ; . Lead and TCE were reported in groundwater and halocarbons were reported in soil gas immediately adjacent to Building 584. Soil samples could not be collected in the former pit due to the obstruction of Building 584; therefore, impacts to soil were not defined. The TCE groundwater plume is moving southwest towards Sites 1 and 3 and co-mingling with plumes delineated at the Sites 1 and 3, and Sites 11 and 13 the Eastern Plume ; Jordan 1990 ; . In June 1992, an interim CERCLA ROD was finalized regarding the Eastern Plume EA and ECC 2005 ; . The Eastern Plume is a dissolved-phase plume comprised predominantly of chlorinated VOCs originating from Sites 4, 11, and 13. In July 1992, a remedial design was prepared for a treatment system that would address the groundwater impacts at Sites 1 and 3 and the Eastern Plume. In 1994, risk-based groundwater target levels were developed for the Eastern Plume, a LTMP was established, and five groundwater extraction wells were installed in the vicinity of the plume. The groundwater extraction and treatment system was activated in 1995 see Section 4.2.1 ; . In a 1998 CERCLA ROD, the selected final remedial action for the site soil was determined to be No Further Action NFA ; because the risk for exposure to soil was below USEPA and ME DEP target levels Navy 1998b ; . Constituent concentrations in groundwater associated with the Eastern Plume still exceeded the risk-based target levels; however, the interim remedial action of groundwater extraction and treatment established in 1992 and activated in 1995 is currently addressing the groundwater impacts EA and ECC 2005 ; . The groundwater treatment system was installed in 1995 included units for chemical oxidation, flocculation, ultraviolet oxidation, clarification, and filtration. Currently the treated water is discharged to the infiltration gallery adjacent to the treatment plant; previously the treated water was discharged to the Brunswick Sewer District. The 1992 CERCLA ROD also established a long-term monitoring program and five-year review submittal for Sites 1 and 3 and the entire Eastern Plume which includes Sites 4, 11, and 13 Navy 1998b and renova. Morning, and were moderated under the auspices of OPS and GE PII, who provided expert facilitators. The full meeting then reconvened to receive brief reports of the individual discussions, although it was not for some time after the Forum that it was possible to summarize into single matrix the reports from each of the five groups. This matrix is now available on PRCI's website at prci , as well as on the OPS site at : primis.rspa.dot.gov rd the latter is particularly well worth visiting and bookmarking, as it contains a considerable depth of information regarding the OPS' actual research programmes, their status, and outcomes ; . The OPS site also contains the presentations made by each of the five groups, reflecting their discussions, and giving a flavour of how the ideas from the Forum were developed. A large number of challenges were identified, and these are too numerous to list here; nevertheless, some of the more important, to this writer at least, are very much worth presenting. The influence of PRCI in the pipeline industry world-wide will undoubtedly become greater as research funds are channelled and unnecessary duplication of research endeavour is eliminated. One of the important and yet unstated outcomes of this Forum may well be greater co-ordination between research-sponsoring organizations, led by PRCI. If this turns out to be the case, it is to be welcomed. In any event, the following is an entirely subjectively-chosen list of issues, needs, and opportunities that will greatly influence where research funds for 2005 will be spent: readers are encouraged to visit the above sites for a more upto-date analysis. Communication was a theme that recurred, both within the industry, and to the wider public. Satellite technology was seen as of developing importance for both surveillance against third-party intrusion ; and for transmission of data. Unmanned `drones' might also achieve the surveillance aim. Support was needed for vendors in commercializing new ideas. Considerable discussion was focussed on the problem of non-piggable pipelines. This, we suggest, together with issues surrounding detection and assessment of stress-corrosion cracking SCC ; , will probably be where the majority of funds will be spent. Acceptable risk was discussed, in terms of `how low is low?' A system of certification for in-line inspection tools and their operators needs to be established. The new API and rebif. Mg123 kg dose of drug used in calculation must be included on written order sheet and reserpine. BALL, H. J., 2002. Veterinary Science Division, Department of Agriculture and Rural Development, Stoney Road, Belfast, BT4 3SD, Northern Ireland. BALL, L., GRINER, L. A. & CARROLL, E. J., 1964. The bovine seminal vesiculitis syndrome. American Journal of Veterinary Research, 25: 291-302. BARAJAS ROJAS, J. A. & BIBERSTEIN, E. L., 1974. The diphtheriod agent of ovine posthitis: Its relationship to Corynebacterium renale. Journal of. Rebif side effects if you experience any of the following serious side effects, stop using rebif, and seek emergency medical attention or contact your doctor immediately: an allergic reaction difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives skin rash, itching, or bumps; depression, anxiety, or suicidal thoughts; seizures; yellowing of the skin or eyes; or unusual bruising or bleeding and restasis. Every time a student reports to the health office with an injury, consider the possibility that the injury might have resulted from an intentional act, either committed by another person or self-inflicted by the student. To determine whether further investigation is warranted, assess whether the history of the incident is consistent with the injury and with your knowledge of the student's abilities. If necessary, you may need to request intervention from a child protection agency. Child maltreatment is illegal, and in most states you are mandated to report even a suspicion of abuse to the appropriate state agency and refresh. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363, 617619 and restoril.